Excess weight can increase the risk of type 2 diabetes, hypertension, and cardiovascular disease. Alli contains orlistat, a lipase inhibitor for overweight adults using a reduced-calorie, lower-fat…
Excess weight can increase the risk of type 2 diabetes, hypertension, and cardiovascular disease. Alli contains orlistat, a lipase inhibitor for overweight adults using a reduced-calorie, lower-fat eating plan. It limits the amount of dietary fat absorbed in the digestive tract.
Alli is an oral capsule containing orlistat, a gastrointestinal lipase inhibitor used as part of weight management for adults who are overweight. Its therapeutic area is obesity, and its ATC classification is A08AB01. The medicine supports a reduced-calorie diet and regular physical activity; it does not replace either one.
The active ingredient is orlistat. It belongs to the lipase inhibitor class.
The dose is decided individually, taking age, other medicines, and health conditions into account. Alli is taken orally as a capsule with meals that contain dietary fat.
Use follows these principles:
Do not take extra orlistat after a meal because more medicine does not remove more calories and can worsen diarrhoea, urgency, and oily discharge. The product is designed for use alongside a reduced-calorie diet rather than unrestricted eating.
One detail patients often miss is that a meal can contain hidden fat from sauces, fried coatings, pastries, creamy dressings, and processed snacks. The bowel reaction may appear later, so linking symptoms to the previous meal is not always obvious.
The active ingredient is orlistat. It belongs to the lipase inhibitor class.
Dietary triglycerides are too large for direct absorption. Gastric and pancreatic lipases normally break them into smaller fatty acids and monoglycerides in the stomach and small intestine.
Orlistat binds to these enzymes in the intestinal lumen and reduces their activity. Less dietary fat is broken down into absorbable components, so part of the fat passes through the intestine without entering the bloodstream. The medicine has limited systemic absorption, which explains why its main effects and adverse reactions occur in the gastrointestinal tract.
Orlistat does not neutralise calories from carbohydrates or protein.
The American Gastroenterological Association describes orlistat as a treatment that can support weight reduction when combined with dietary and behavioural measures [1].
Alli is an oral capsule containing orlistat, a gastrointestinal lipase inhibitor used as part of weight management for adults who are overweight. The medicine supports a reduced-calorie diet and regular physical activity; it does not replace either one.
Several practical errors reduce the value of treatment or increase adverse effects:
A capsule taken with a fat-free meal may provide little useful action. A capsule taken with a very fatty meal may create a disproportionate bowel reaction. The amount and distribution of fat matter.
Alli is not suitable for every adult with excess weight. It must not be used by people with chronic malabsorption syndrome or cholestasis, a condition in which bile flow from the liver is impaired.
Treatment requires careful medical assessment in people with:
Pregnancy is a clear exclusion because weight loss offers no treatment benefit during pregnancy and nutritional needs are different.
The most important interactions involve ciclosporin and warfarin.
| Medicine or group | Main concern | Practical management |
|---|---|---|
| Ciclosporin | Reduced ciclosporin exposure may weaken immunosuppression | Avoid routine combination unless specialist monitoring is arranged |
| Warfarin and other vitamin K-sensitive anticoagulation | Reduced vitamin K absorption may alter anticoagulant control | Closer coagulation monitoring may be required |
| Levothyroxine, some antiseizure medicines, and antiretroviral treatment | Absorption or clinical control may change | Individual timing, monitoring, or an alternative may be needed |
The Food and Drug Administration prescribing information describes these interaction and vitamin-absorption precautions [2].
Alli is not for you if you have chronic malabsorption syndrome, cholestasis, or another condition in which fat absorption is already impaired. Combining two causes of poor fat absorption can increase nutritional risk.
Avoid self-directed use during pregnancy. Breastfeeding also needs individual assessment because weight loss, maternal nutrient intake, and infant feeding must be considered together.
Extra caution is required with:
A person with persistent diarrhoea, unexplained weight loss, or an eating disorder needs assessment before using a fat-blocking medicine. Alli is intended for weight management, not for unexplained weight loss.
Gastrointestinal reactions are the characteristic adverse effects of orlistat. They result from undigested fat reaching the lower bowel.
Possible effects include:
These effects are more likely after a high-fat meal. They may reduce when meals contain less fat and when fat is distributed more evenly throughout the day.
Fat-soluble vitamin deficiency is a longer-term concern. Signs can be non-specific, including unusual tiredness, changes in night vision, easy bruising, or bone and muscle symptoms. Such symptoms have many possible causes, so they need clinical evaluation rather than automatic vitamin escalation.
Serious reactions are uncommon but require prompt attention. Severe or persistent abdominal pain, symptoms of liver injury, allergic swelling, breathing difficulty, or signs of kidney problems should not be ignored.
Alli uses a lower-dose, non-prescription orlistat approach for suitable adults. Prescription-strength orlistat contains the same active substance at a higher dose and requires a clinician to assess whether the additional exposure is appropriate.
| Approach | Main action | Typical clinical setting |
|---|---|---|
| Alli | Reduces digestion and absorption of some dietary fat | Adult weight management with diet and activity changes |
| Prescription-strength orlistat | Same lipase-inhibiting mechanism at a higher strength | Clinician-supervised obesity treatment |
| Lifestyle treatment without orlistat | Reduces energy intake and increases energy expenditure | Foundation of weight management for every patient |
The difference is pharmacological strength, not a completely different mechanism. Higher exposure can increase gastrointestinal adverse effects, so a stronger formulation is not automatically a better choice.
Weight reduction depends on sustained calorie control. If there is little progress after a reasonable trial with dietary changes, the treatment plan may need review. The European Medicines Agency has evaluated orlistat-containing products within the wider framework of obesity treatment and risk management [3].
In clinical practice, doctors usually explain that orlistat works best when the eating pattern changes from the first day. It does not directly reduce hunger, improve mood, or increase exercise capacity. Its role is narrower: it limits absorption of part of the fat eaten with a meal.
A doctor will usually review weight trend, bowel tolerability, nutrition, and concurrent medicines. The response should be judged over time rather than after one or two capsules. A person who experiences severe bowel effects may be eating more fat than the treatment plan allows, but persistent symptoms can also indicate intolerance or another gastrointestinal condition.
The World Health Organization treats obesity as a chronic, relapsing disease influenced by biological, environmental, and behavioural factors [4]. That perspective helps set realistic expectations: a capsule can support a wider plan, while long-term weight maintenance still depends on eating habits, activity, sleep, and follow-up.
Orlistat acts locally during digestion of the meal with which it is taken. It does not provide a prolonged appetite-suppressing effect after the meal, and it does not remove fat from later meals automatically. The FDA’s 2019 patient information describes dosing in relation to meals rather than as a continuous effect throughout the day [5]. A meal with little or no fat creates less substrate for orlistat to act on.
Alli is intended for adults, not routine use in children or younger teenagers. Weight management in someone under 18 requires assessment of growth, puberty, nutrition, mental health, and possible medical causes of weight change. Medsafe guidance from 2024 and paediatric obesity guidance emphasise age-appropriate assessment rather than adult self-treatment. A young person should not use an adult weight-loss medicine without a clinician-led plan.
The capsule should be swallowed whole with water. Splitting, crushing, or chewing can make administration unpleasant and may interfere with the intended dosage form. The FDA’s 2019 product information describes oral capsule administration as the standard method. If swallowing is difficult, a clinician or pharmacist can identify a suitable alternative approach instead of altering the capsule.
Alcohol does not provide the dietary fat that triggers orlistat’s main gastrointestinal effect, yet it adds calories and can undermine a reduced-calorie weight-management plan. Alcohol may also worsen nausea, diarrhoea, dehydration, or poor food choices in some people. WHO’s 2024 nutrition guidance supports limiting alcohol as part of broader health management. Anyone using medicines for diabetes, anticoagulation, liver disease, or mental health needs a separate interaction review.
Weight-loss treatment with Alli should not be used during pregnancy. Pregnancy requires adequate energy and nutrient intake, and intentional weight reduction is not the treatment goal. Breastfeeding requires individual assessment because maternal fat-soluble vitamin status and infant nutrition both matter. EMA’s 2018 safety information for orlistat products identifies pregnancy as a situation in which routine weight-loss treatment is inappropriate.
Both approaches use orlistat to inhibit gastrointestinal lipases and reduce absorption of some dietary fat. The main difference is the amount of active substance and the level of clinical supervision. A higher-strength prescription formulation can produce stronger gastrointestinal effects without changing the underlying mechanism. Medsafe information from 2024 and EMA information from 2018 support checking the exact formulation before switching between strengths.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 3 reviews
The first few days were awkward because I underestimated how much fat was in takeaway food. Once I changed my meals, the urgency settled and keeping track of food became easier.
Te Awamutu Several weeks 27 Oct 2026I expected appetite suppression, so I was disappointed. The bowel effects were manageable on lighter meals, but I did not want to continue because the treatment did not fit my routine.
Pukekohe A short trial 3 Nov 2026Weight loss was gradual rather than dramatic. I found the vitamin timing and meal planning annoying at first, yet the lower-fat routine became easier after a few weeks.
Auckland A few weeks 6 Oct 2026
